EHA 2016 | The unmet need in DLBCL

Name: The unmet need in DLBCL
Uploaded: 2016-04-18T00:00:00.000Z
Duration: 43 s
Description: Georg Lenz from the University of Münster, Münster, Germany discusses the current unmet need in diffuse large B-cell lymphoma (DLBCL), which he states to be patients who do not respond to the current standard treatment of rituximab plus CHOP chemotherapy. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

Georg Lenz • 18 Apr 2016

EHA 2016

B-Cell Lymphoma Diffuse Large B-Cell Lymphoma Non-Hodgkin Lymphoma Rituximab

Georg Lenz from the University of Münster, Münster, Germany discusses the current unmet need in diffuse large B-cell lymphoma (DLBCL), which he states to be patients who do not respond to the current standard treatment of rituximab plus CHOP chemotherapy. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.